Incyte Names Stamoulis as Chief Financial Officer
4 January 2019 - - US-based biopharmaceutical company Incyte (NASDAQ: INCY) has appointed Christiana Stamoulis as executive vice president and chief financial officer, effective 11 February, the company said.

Stamoulis will succeed David Gryska who, as planned, retired from Incyte at the end of 2018.

Stamoulis has over 20 years of experience in the biotechnology industry. She joins Incyte from Unum Therapeutics, where she was president and chief financial officer.

Prior to Unum, she was the senior vice president of corporate strategy and business development at Vertex Pharmaceuticals.

Prior to joining Vertex, she spent nearly 15 years in the investment banking and management consulting industries.

She was a managing director at Citigroup's Investment Banking division and prior to that, she was a senior investment banker in the Healthcare Investment Banking Group at Goldman Sachs, where she spent the majority of her investment banking career.

Stamoulis started her career as a strategy consultant at The Boston Consulting Group. Stamoulis serves on the board of directors of Hologic Inc., a medical technology company.

Incyte Corp. is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.